Physician profile
Derek Higgins
NPI 1538865308
$6,854.11
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $2,733 · 2024: $4,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,773 · Education: $80.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,773.12 |
| Education | $80.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $1,114.62 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Otsuka America Pharmaceutical, INC. | $774.42 | 2023-2024 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Abbvie INC. | $772.42 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $749.58 | 2023-2024 | Invega Sustenna, Spravato |
| Teva Pharmaceuticals USA, INC. | $726.25 | 2023-2024 | Austedo Xr, Uzedy, Austedo |
| Indivior INC. | $521.10 | 2023-2024 | Perseris |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $516.89 | 2023-2024 | Caplyta |
| Lundbeck LLC | $453.95 | 2023-2024 | Rexulti, Brintellix |
| Neurocrine Biosciences, INC. | $403.37 | 2023-2024 | Ingrezza |
| Vanda Pharmaceuticals INC. | $249.77 | 2023-2024 | Hetlioz, Fanapt |
| Axsome Therapeutics, INC. | $206.89 | 2023-2024 | Auvelity |
| Supernus Pharmaceuticals, INC. | $98.84 | 2024 | Qelbree |
| E.R. Squibb & Sons, L.L.C. | $90.53 | 2024 | Cobenfy |
| Corium, LLC | $62.39 | 2023 | Azstarys |
| Noven Therapeutics, LLC | $37.94 | 2023-2024 | Secuado, Xelstrym |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.92 | 2023 | Belsomra |
| Eisai INC. | $18.98 | 2023 | |
| Biogen, INC. | $15.74 | 2024 | |
| Tris Pharma INC | $13.69 | 2023 | Dyanavel Xr |
| Janssen Scientific Affairs, LLC | $6.82 | 2024 | Invega Sustenna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Higgins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.